Skip to main content
. 2011 Jan 25;16(2):155–164. doi: 10.1634/theoncologist.2010-0350

Figure 2.

Figure 2.

Kaplan–Meier curves of progression-free survival (A) and overall survival (B) for patients with human epidermal growth factor receptor 2–positive tumors by whether they received trastuzumab.